Inflammatory patterns of allergic and nonallergic rhinitis

Sobol, Steven E.; Christodoulopoulos, Pota; Hamid, Qutayba

doi:10.1007/s11882-001-0005-7

Cited by 7 publications

(5 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…91 On a population level, non-allergic atopic manifestations have a higher age of onset, have more severe symptoms and a female pre-dominance compared to allergic forms of the same disorders. 91,92 Although allergic atopic inflammation differs from a nonallergic atopic inflammation with regards to immune cells involved, cytokine patterns and antibody production, 93 there is no scientific consensus as to whether these differences are negligible or important markers of two truly distinct forms of disease. For the biologic rationale of this study it is important to note that besides the localized inflammation, these diseases are associated with multiple systemic manifestations and also have neuromodulatory properties.…”

Section: Atopymentioning

confidence: 99%

Low Levels of Antibodies Against Phosphorylcholine in Alzheimer's Disease

Eriksson

Sjöberg

Bennet

et al. 2010

JAD

View full text Add to dashboard Cite

Phosphorylcholine (PC) may play an important role in the atherogenic and pro-inflammatory effects of oxidized low density lipoproteins. We recently demonstrated that low levels of IgM antibodies against PC (anti-PC) are associated with development of myocardial infarction and stroke. We here evaluate the association between anti-PC and dementia and Alzheimer's disease (AD). We conducted a nested case-control study of 182 incident dementia cases (serum collected before onset of dementia) matched to 366 controls and a case-control study of 97 prevalent dementia cases (serum collected after dementia onset) matched to 205 controls. Controls were matched on gender and age at blood draw (+/- 1 year). Participants were from the Swedish Twin Registry. Anti-PC levels were measured by ELISA. The odds ratio (OR) of dementia was modeled using conditional logistic regression. Patients with dementia had significantly lower mean anti-PC levels than controls (39.1 versus 49.5 U/ml). The likelihood of having dementia or AD was doubled for individuals with the lowest 25% anti-PC levels (OR=2.04 and 2.70, respectively). The results were similar after adjustments for potential confounders. There was no association between anti-PC levels and incident dementia. Low levels of atheroprotective anti-PC could play a role in AD and dementia. Potential mechanisms include decreased anti-inflammatory potential and effects on the vasculature. Further attention is merited to elucidate the role of anti-PC in AD development and the usefulness of anti-PC as a part of risk prediction, prognosis, diagnosis, or treatment.

show abstract

Section: Atopymentioning

confidence: 99%

Low Levels of Antibodies Against Phosphorylcholine in Alzheimer's Disease

Eriksson

Sjöberg

Bennet

et al. 2010

JAD

View full text Add to dashboard Cite

show abstract

“…Allergic disorders are complex and multifactorial diseases which imply formation and release of several different mediators [1,2]. Antigenic challenge causes the release of histamine by mast cells and basophils, leading to contraction of the bronchial smooth muscles, vasodilation and an increase in vascular permeability, as well as increased secretion by the respiratory epithelium cells [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Central and Peripheral Evaluation of Rupatadine, a New Antihistamine/Platelet-Activating Factor Antagonist, at Different Doses in Healthy Volunteers

et al. 2004

View full text Add to dashboard Cite

Aims: To assess peripheral anti-H₁ and central nervous system (CNS) activity of single increasing doses of rupatidine fumarate (RU), a new antihistamine/platelet-activating factor antagonist compound, in comparison with hydroxyzine and placebo. Methods: Eighteen healthy young subjects of both sexes took part in a crossover, randomised, double-blind, placebo-controlled study. Treatments tested were: RU 10, 20, 40 and 80 mg and hydroxyzine 25 mg, as a positive standard. Before and several times after drug intake, peripheral anti-H₁ activity was appraised by the skin reactivity to intradermal injection of histamine. CNS effects were also obtained by objective tests of psychomotor performance and subjective mood scales. Results: All active treatments showed a significant reduction of the wheal and flare reaction in relation to placebo, RU displaying a potent dose-dependent inhibition pattern. The global nonparametric Friedman test to changes from placebo in 15 objective variables from psychomotor performance showed a significant impairment of similar magnitude after hydroxyzine 25 mg (p = 0.01) and RU 80 mg (p = 0.02), but this was slower in development and recovery after the latter. After RU 40 mg, a smaller impairment was also obtained (p = 0.04). Activity (p = 0.01) and drowsiness (p = 0.02) scales showed significant changes, the subjects feeling less active and more drowsy after all active treatments. Conclusion: RU presents a potent dose-dependent peripheral anti-H₁ activity, displaying psychomotor impairment activity only at the highest dose (80 mg), while therapeutically relevant lower doses (10 and 20 mg) were similar to placebo.

show abstract

“…In humans, allergic and nonallergic rhinitis can be distinguished to some extent by the pattern of inflammation induced, which can be classified by histologic characteristics and cytokine profiles. 7 Allergen-induced responses result in nasal eosinophilia and generate primarily a Th2 response, with increases in interleukin (IL)-4, IL-5, and IL-13 to initiate the humoral immune response. A range of severity and type of inflammation characterizes nonallergic rhinitis, and this heterogenous group of disorders is associated with variable and mixed immune profiles.…”

mentioning

confidence: 99%